This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
ICD-10: D80.0 | Synonyms: familial hypogammaglobulinemia, Familial hypogammaglobulinaemia, congenital hypogammaglobulinemia
The history of immunoglobulin deficiency diseases begins with Bruton's description of agammaglobulinemia in 1952. Subsequently, a group of hereditary diseases showing hypogammaglobulinemia (markedly decreased but with some remaining), milder than agammaglobulinemia, began to be classified separately. With the introduction of immunoelectrophoresis and immunodiffusion in the 1960s–1970s, various immunoglobulin deficiency phenotypes could be evaluated quantitatively.
Hereditary hypogammaglobulinemia is not a single disease but a heterogeneous group of diseases caused by multiple genetic causes. As various gene variants were identified as causes over the 1980s–1990s, congenital/hereditary hypogammaglobulinemia was established as a separate disease classification system.
From the 1990s to the 2010s, various genes involved in B cells and antibody production, such as NFKB1, NFKB2, CARD11, PIK3CD, PIK3R1, LRBA, CTLA4, were discovered as causes of hereditary hypogammaglobulinemia. This contributed to understanding the complex molecular network of B cell development and maintenance of function.
In Korea, as awareness of primary immunodeficiency diseases increased, diagnosed cases of hereditary hypogammaglobulinemia began to be reported from the late 1990s. It is currently registered as a rare disease, and improvements in genetic diagnosis and access to specialized immunology clinics are continuing.
Hereditary hypogammaglobulinemia is caused by abnormalities in various genes involved in B cell development, function, or antibody secretion. It includes not only blockage of B cell development itself but also cases in which B cells are present but functional differentiation or antibody production capacity is reduced, resulting in hypogammaglobulinemia.
NFKB1 (NF-κB p50) and NFKB2 (NF-κB p52) proteins are transcription factors essential for immune cell development and survival. Heterozygous variants of NFKB1 mainly cause a common variable immunodeficiency (CVID)-like phenotype, and NFKB2 variants are sometimes accompanied by hypogammaglobulinemia and hypopituitarism.
Loss-of-function variants of the CARD11 gene impair NF-κB signaling in B cells and T cells, causing hypogammaglobulinemia. Deficiency of the LRBA (LPS-responsive beige-like anchor protein) gene causes impaired recycling of CTLA-4, resulting in a phenotype combining autoimmunity and immunodeficiency.
PI3Kδ overactivation (activated PI3K delta syndrome, APDS) is caused by gain-of-function variants of PIK3CD and results in abnormal B cell maturation and hypogammaglobulinemia.
Hereditary hypogammaglobulinemia has different modes of inheritance depending on the causative gene. Various modes of inheritance exist, including autosomal dominant inheritance (NFKB1, NFKB2, CARD11 loss of function, PIK3CD gain of function, CTLA4), autosomal recessive inheritance (LRBA, ICOS, CD81, etc.), and X-linked recessive inheritance (XLA due to BTK variants).
Autosomal dominant forms (e.g., NFKB1 heterozygous variants) are characterized by incomplete penetrance and variable expressivity, with phenotypes varying even within the same family. Some carriers show normal immune function, while others show mild to severe hypogammaglobulinemia.
In some patients, the disease arises from de novo variants without a family history, and CARD11 and PIK3CD gain-of-function variants have been reported to occur de novo.
The exact incidence of hereditary hypogammaglobulinemia varies greatly by causative gene, and overall it is a rare disease. NFKB1 heterozygous variants may show a prevalence similar to that of common variable immunodeficiency (1/25,000–1/50,000).
Depending on the causative gene and mode of inheritance, it is diagnosed at various ages, including childhood, adolescence, and adulthood. When the mode of inheritance is autosomal, both men and women can be affected.
In Korea, systematic epidemiological studies of hereditary hypogammaglobulinemia among primary immunodeficiency diseases are lacking, but with the Korean primary immunodeficiency registry program and the introduction of next-generation sequencing, diagnosed cases of patients with various causative gene variants are increasing.
The pathogenesis of hereditary hypogammaglobulinemia can be broadly divided into two categories. First, cases due to blockage of B cell development itself (early developmental defects) (BTK, IGHM deficiency, etc.), and second, cases in which B cell development is normal but there is reduced functional maturation and antibody secretion capacity (late differentiation defects) (NFKB1, LRBA, CTLA4 variants, etc.).
NF-κB signaling is essential for B cell survival, proliferation, and differentiation. With NFKB1 or NFKB2 variants, mature B cells are present, but final differentiation into antibody-secreting plasma cells and antibody production capacity are reduced. In this case, a hypogammaglobulinemia phenotype is seen rather than typical agammaglobulinemia.
The LRBA protein regulates intracellular recycling of the CTLA-4 receptor. In LRBA deficiency, CTLA-4 is degraded, leading to overactivation of T cells and B cells and autoimmunity, accompanied paradoxically by immunodeficiency.
Recurrent bacterial infections (pneumonia, sinusitis, otitis media) are the main symptoms, and infection frequency and severity may be somewhat lower than in agammaglobulinemia. Chronic lung disease progressing to bronchiectasis is common. Patients are also vulnerable to herpesvirus and enterovirus infections.
Autoimmune diseases frequently accompany hereditary hypogammaglobulinemia. Autoimmune thrombocytopenia, autoimmune hemolytic anemia, autoimmune neutropenia, inflammatory bowel disease, arthritis, and others may occur. Autoimmune complications are particularly prominent with LRBA, CTLA4, and CARD11 variants.
Some patients develop lymphadenopathy, splenomegaly, and granulomatous disease. The risk of lymphoma may be increased in hereditary hypogammaglobulinemia showing a CVID-like phenotype.
Unlike agammaglobulinemia, lymphadenopathy or splenomegaly may actually be observed. Bronchiectasis and chronic sinusitis due to recurrent infections are found. Pallor (anemia), petechiae (thrombocytopenia), and joint swelling due to autoimmune complications are sometimes observed.
Serum IgG is markedly lower than the lower limit of normal for age, and IgA and IgM are also decreased, but often not to completely undetectable levels. Peripheral blood B cell counts vary by cause and may be normal or decreased. Antigen-specific antibody responses (antibody production after vaccination) are reduced.
Chest CT: bronchiectasis, pulmonary nodules (granulomas). Abdominal ultrasound/CT: splenomegaly, lymphadenopathy. Abnormal pituitary MRI findings are observed in some patients with NFKB2 variants.
Immunodeficiency should be suspected in children or adults who have experienced recurrent bacterial infections, or in patients with autoimmune complications combined with susceptibility to infection. When there is a family history, screening of siblings and parents is recommended.
Quantification of serum IgG, IgA, and IgM is the most basic and important screening test. When hypogammaglobulinemia below the age-based lower limit of normal is confirmed, further testing proceeds.
Functional antibody production capacity is evaluated by measuring specific antibody responses after vaccination (pneumococcal polysaccharide vaccine, tetanus vaccine). Failure of antibody response suggests functional hypogammaglobulinemia.
After decreased serum immunoglobulins and lymphocyte subset abnormalities are confirmed, the causative variant is identified with an NGS panel (NFKB1, NFKB2, CARD11, LRBA, PIK3CD, PIK3R1, CTLA4, ICOS, BTK, etc.) including primary immunodeficiency causative genes.
When no cause is found by panel testing, new causative genes or atypical variants can be discovered through whole exome sequencing (WES) or whole genome sequencing (WGS).
To confirm the pathological significance of gene variants, functional tests such as T/B cell function tests, measurement of NF-κB activation, PI3K signaling analysis, and measurement of CTLA-4 surface expression are used as adjunctive diagnostics.
With recurrent infections or IgG < 5–6 g/L, IVIG or SCIG replacement therapy is started. The target is maintaining an IgG trough of 8 g/L or more, and the target is raised according to infection frequency and pulmonary complications.
Immunosuppressive therapy (steroids, rituximab, mycophenolate) is given for autoimmune thrombocytopenia and hemolytic anemia. In LRBA deficiency, administration of CTLA-4 Ig (abatacept, belatacept) effectively improves autoimmunity and immune dysregulation. For PIK3CD gain-of-function variants, administration of PI3Kδ inhibitors (leniolisib, idelalisib) is under research and clinical application.
In LRBA deficiency, CARD11 loss of function, and some severe hereditary hypogammaglobulinemias, hematopoietic stem cell transplantation (HSCT) may be performed with the aim of cure. Transplantation is considered especially when autoimmune complications and immunodeficiency are severe.
Prognosis varies depending on the causative gene and clinical phenotype. In patients whose infections are well controlled with IgRT, a relatively normal quality of life can be maintained. Patients with LRBA deficiency, CTLA4 variants, or CARD11 loss of function with severe autoimmune complications need aggressive treatment such as immunosuppressive therapy and HSCT.
Chronic lung disease (bronchiectasis), autoimmune organ damage, granulomatous disease, and lymphoma are the main factors determining long-term prognosis. Early detection and treatment of these complications through regular follow-up is important.
Genetic counseling and carrier testing of family members are important. In autosomal dominant forms, one of the parents may be a carrier, so both sides of the family are tested. Prenatal diagnosis and preimplantation genetic testing (PGT-M) options are offered.
Maintenance of regular IgRT, caution with live vaccines, early antibiotic treatment for infections, and regular monitoring of lung function are recommended.
Autoimmune complications are detected early and treated through regular autoimmune marker tests, blood counts, and organ function assessment.